| 臺大學術典藏 |
2022-06-10T06:11:12Z |
Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma
|
Hsu C.-H.; Yang T.-S.; Hsu C.; Toh H.C.; Epstein R.J.; Hsiao L.-T.; Chen P.-J.; ZHONG-ZHE LIN; Chao T.-Y.; Cheng A.-L. |
| 臺大學術典藏 |
2022-01-12T07:07:28Z |
Pharmacokinetic profile and first preliminary clinical evaluation of bendamustine in Taiwanese patients with heavily pretreated indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
|
Hsiao L.-T.; Tien H.-F.; Kuo C.-Y.; Wu J.-H.; HSIN-AN HOU; Wang M.-C.; Liu C.-Y.; Chen P.-M.; Chiou T.-J. |
| 臺大學術典藏 |
2021-09-01T01:54:16Z |
Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma
|
Hsu C.-H.; Yang T.-S.; Hsu C.; Toh H.C.; Epstein R.J.; Hsiao L.-T.; Chen P.-J.; Lin Z.-Z.; Chao T.-Y.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-11T03:46:49Z |
Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma
|
Hsu C.-H.; Yang T.-S.; Hsu C.; Toh H.C.; Epstein R.J.; Hsiao L.-T.; Chen P.-J.; ZHONG-ZHE LIN; Chao T.-Y.; Cheng A.-L. |
| 臺大學術典藏 |
2021-07-03T03:34:46Z |
Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma
|
Hsu C.-H.; Yang T.-S.; Hsu C.; Toh H.C.; Epstein R.J.; Hsiao L.-T.; PEI-JER CHEN; Lin Z.-Z.; Chao T.-Y.; Cheng A.-L. |
| 臺大學術典藏 |
2021-02-05T06:29:19Z |
Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher-risk myelodysplastic syndromes
|
Wen-Chien Chou;Yeh S.-P.;Hsiao L.-T.;Lin S.-F.;Chen Y.-C.;Chen T.-Y.;Laille E.;Galettis A.;Dong Q.;Songer S.;Beach C.L.; WEN-CHIEN CHOU; Yeh S.-P.; Hsiao L.-T.; Lin S.-F.; Chen Y.-C.; Chen T.-Y.; Laille E.; Galettis A.; Dong Q.; Songer S.; Beach C.L. |
| 臺大學術典藏 |
2021-02-03T03:28:39Z |
Human cytokine genetic variants associated with HBsAg reverse seroconversion in rituximab-treated non-hodgkin lymphoma patients
|
Hsiao L.-T.; Wang H.-Y.; Yang C.-F.; Chiou T.-J.; Gau J.-P.; Yu Y.-B.; Liu H.-L.; WEN-CHUN CHANG; Chen P.-M.; Tzeng C.-H.; Chan Y.-J.; Yang M.-H.; Liu J.-H.; Huang Y.-H. |
| 臺大學術典藏 |
2021-01-06T03:58:43Z |
Haematopoietic stem cell transplantation in Taiwan: Past, present, and future
|
Chen P.M.; Hsiao L.T.; JIH-LUH TANG; Yen C.C.; Liu J.H.; Chiou T.J.; Tzeng C.H.; Lin K.H. |
| 臺大學術典藏 |
2020-04-28T07:25:28Z |
Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma
|
Chih-Hung Hsu;Yang T.-S.;Hsu C.;Toh H.C.;Epstein R.J.;Hsiao L.-T.;Chen P.-J.;Lin Z.-Z.;Chao T.-Y.;Cheng A.-L.; CHIH-HUNG HSU; Yang T.-S.; Hsu C.; Toh H.C.; Epstein R.J.; Hsiao L.-T.; Chen P.-J.; Lin Z.-Z.; Chao T.-Y.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:20Z |
Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma
|
Hsu C.-H.;Yang T.-S.;Chiun Hsu;Toh H.C.;Epstein R.J.;Hsiao L.-T.;Chen P.-J.;Lin Z.-Z.;Chao T.-Y.;Cheng A.-L.; Hsu C.-H.; Yang T.-S.; Chiun Hsu; Toh H.C.; Epstein R.J.; Hsiao L.-T.; Chen P.-J.; Lin Z.-Z.; Chao T.-Y.; Cheng A.-L. |
| 臺大學術典藏 |
2018-09-10T07:46:58Z |
Haematopoietic stem cell transplantation in Taiwan: Past, present, and future
|
Chen, P.M.;Hsiao, L.T.;Tang, J.L.;Yen, C.C.;Liu, J.H.;Chiou, T.J.;Tzeng, C.H.;Lin, K.H.; KAI-HSIN LIN |
| 國立成功大學 |
2017 |
Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher-risk myelodysplastic syndromes
|
Chou, W.-C.;Yeh, S.-P.;Hsiao, L.-T.;Lin, S.-F.;Chen, Y.-C.;Chen, T.-Y.;Laille, E.;Galettis, A.;Dong, Q.;Songer, Songer S.;Beach, C.L. |
| 臺大學術典藏 |
2015 |
The board of directors and corporate social performance under weak institutions
|
CHENG-MIN CHUANG; Chuang, C.-M.; Hsiao, L.-T.; Lin, C.-P.; Lin, C.-P.;Hsiao, L.-T.;Chuang, C.-M. |
| 臺大學術典藏 |
2015 |
Pharmacokinetic profile and first preliminary clinical evaluation of bendamustine in Taiwanese patients with heavily pretreated indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
|
Kuo C.-Y.; Hsiao L.-T.; HWEI-FANG TIEN; Wu J.-H.; Hou H.-A.; Wang M.-C.; Liu C.-Y.; Chen P.-M.; Chiou T.-J. |
| 國立成功大學 |
2014-06-01 |
A PHASE 4, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF SUBCUTANEOUS AZACITIDINE IN ADULT TAIWANESE SUBJECTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES
|
Chou, W. C.; Yeh, S. P.; Hsiao, L. T.; Lin, S. F.; Chen, Y. C.; Chen, T. Y.; Wang, J. Y.; Galettis, A.; Dong, Q.; Songer, S.; Beach, C. |
| 臺大學術典藏 |
2010 |
Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma
|
Hsu C.-H.; Yang T.-S.; CHIUN HSU; Toh H.C.; Epstein R.J.; Hsiao L.-T.; Chen P.-J.; Lin Z.-Z.; Chao T.-Y.; Cheng A.-L. |
| 國立成功大學 |
2002-06 |
Endofem integrated methodology for fatigue crack growth
|
Lee, Chau-Fei; Hsiao, L. T. |
| 國立成功大學 |
2000-12 |
EndoFEM crack closure analysis of AL2024-T3 CCT specimen under all tension fatigue loading
|
Lee, Chau-Fei; Hsiao, L. T. |
